Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study.

COVID-19 FIASMA SARS-CoV-2 antidepressant ceramide mortality

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
04 Aug 2023
Historique:
received: 26 05 2023
revised: 12 07 2023
accepted: 20 07 2023
medline: 26 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

Prior evidence indicates the potential central role of the acid sphingomyelinase (ASM)/ceramide system in the infection of cells with SARS-CoV-2. We conducted a multicenter retrospective observational study including 72,105 adult patients with laboratory-confirmed SARS-CoV-2 infection who were admitted to 36 AP-HP (Assistance Publique-Hôpitaux de Paris) hospitals from 2 May 2020 to 31 August 2022. We examined the association between the ongoing use of medications functionally inhibiting acid sphingomyelinase (FIASMA), which reduces the infection of cells with SARS-CoV-2 in vitro, upon hospital admission with 28-day all-cause mortality in a 1:1 ratio matched analytic sample based on clinical characteristics, disease severity and other medications (N = 9714). The univariate Cox regression model of the matched analytic sample showed that FIASMA medication use at admission was associated with significantly lower risks of 28-day mortality (HR = 0.80; 95% CI = 0.72-0.88;

Identifiants

pubmed: 37631022
pii: ph16081107
doi: 10.3390/ph16081107
pmc: PMC10458150
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

PLoS One. 2011;6(8):e23852
pubmed: 21909365
Mol Psychiatry. 2022 Apr;27(4):1898-1907
pubmed: 34997196
Cell Rep Med. 2020 Nov 17;1(8):100142
pubmed: 33163980
Lancet. 2023 Jan 28;401(10373):281-293
pubmed: 36566761
Int J Mol Sci. 2021 Apr 30;22(9):
pubmed: 33946479
Br J Clin Pharmacol. 2021 Oct;87(10):3766-3775
pubmed: 33608891
J Virol. 2022 Dec 21;96(24):e0124522
pubmed: 36468859
Mol Psychiatry. 2022 Jan;27(1):307-314
pubmed: 34608263
Cureus. 2020 May 12;12(5):e8069
pubmed: 32411566
Sci Rep. 2021 Mar 15;11(1):5890
pubmed: 33723270
Open Forum Infect Dis. 2021 Feb 01;8(2):ofab050
pubmed: 33623808
JAMA. 2020 Dec 8;324(22):2292-2300
pubmed: 33180097
Mol Psychiatry. 2022 Mar;27(3):1278-1280
pubmed: 34837060
JAMA Intern Med. 2022 Jan 1;182(1):19-25
pubmed: 34747982
Int J Pharm. 2021 Sep 25;607:121023
pubmed: 34416332
PLoS One. 2021 Feb 19;16(2):e0247122
pubmed: 33606790
Inform Med Unlocked. 2021;24:100597
pubmed: 34075338
JAMA Netw Open. 2021 Nov 1;4(11):e2133090
pubmed: 34779847
Int J Mol Sci. 2022 Nov 07;23(21):
pubmed: 36362409
Ann Transl Med. 2019 Jan;7(1):16
pubmed: 30788363
J Med Virol. 2020 Oct;92(10):1733-1734
pubmed: 32242950
J Affect Disord. 2016 Nov 15;205:1-12
pubmed: 27389296
World Psychiatry. 2022 Jun;21(2):314-315
pubmed: 35524600
Clin Drug Investig. 2021 Mar;41(3):221-233
pubmed: 33559821
Open Forum Infect Dis. 2022 Aug 03;9(8):ofac389
pubmed: 36000003
JAMA Netw Open. 2022 Nov 1;5(11):e2242140
pubmed: 36378313
Mol Psychiatry. 2023 Mar 3;:
pubmed: 36869228
Cell Physiol Biochem. 2010;26(1):9-20
pubmed: 20502000
Pharmaceuticals (Basel). 2022 Mar 21;15(3):
pubmed: 35337177
Epidemiol Psychiatr Sci. 2022 Mar 30;31:e18
pubmed: 35352674
J Biol Chem. 2021 Jan-Jun;296:100701
pubmed: 33895135
Nat Med. 2020 Sep;26(9):1417-1421
pubmed: 32665655
Pharmaceuticals (Basel). 2021 Mar 07;14(3):
pubmed: 33799977
Microorganisms. 2021 Feb 09;9(2):
pubmed: 33572117
Mol Psychiatry. 2021 Dec;26(12):7098-7099
pubmed: 34385600
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Biol Psychiatry Glob Open Sci. 2023 Jan;3(1):56-67
pubmed: 35013734
JCI Insight. 2023 May 22;8(10):
pubmed: 37212278
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
J Med Chem. 2008 Jan 24;51(2):219-37
pubmed: 18027916
Molecules. 2023 Mar 27;28(7):
pubmed: 37049752
Emerg Microbes Infect. 2020 Dec;9(1):2245-2255
pubmed: 32975484
Front Pharmacol. 2021 Apr 20;12:652688
pubmed: 33959018
Br J Pharmacol. 2021 Jun;178(11):2339-2350
pubmed: 33825201
JAMA Netw Open. 2021 Nov 1;4(11):e2136510
pubmed: 34779851
Ideggyogy Sz. 2021 Nov 30;74(11-12):389-396
pubmed: 34856085
Transl Psychiatry. 2022 Aug 22;12(1):341
pubmed: 35995770
Addiction. 2011 Oct;106(10):1871-2
pubmed: 21917042
Br J Clin Pharmacol. 2022 May;88(5):2065-2073
pubmed: 34719789
Mol Psychiatry. 2021 Sep;26(9):5199-5212
pubmed: 33536545
Clin Pharmacol Ther. 2021 Dec;110(6):1498-1511
pubmed: 34050932
J Travel Med. 2022 May 31;29(3):
pubmed: 35137210
Transl Psychiatry. 2022 Mar 3;12(1):90
pubmed: 35241663
Encephale. 2020 Jun;46(3):193-201
pubmed: 32370982
Clin Microbiol Infect. 2023 May;29(5):578-586
pubmed: 36657488
Pharmaceutics. 2021 Sep 03;13(9):
pubmed: 34575474
J Clin Med. 2021 Dec 15;10(24):
pubmed: 34945186
Sci Rep. 2021 Nov 4;11(1):21633
pubmed: 34737330
J Clin Med. 2022 Oct 05;11(19):
pubmed: 36233753
J Travel Med. 2021 Feb 23;28(2):
pubmed: 33506243
J Clin Epidemiol. 2013 Aug;66(8 Suppl):S84-S90.e1
pubmed: 23849158
Sci Rep. 2021 Oct 21;11(1):20866
pubmed: 34675292
Biomed Pharmacother. 2021 Jun;138:111437
pubmed: 33691249
BJPsych Open. 2021 Dec 03;8(1):e6
pubmed: 34859759
Braz J Psychiatry. 2023 Jun 08;:
pubmed: 37290011
Int J Mol Sci. 2021 Sep 22;22(19):
pubmed: 34638539
Lancet Glob Health. 2022 Jan;10(1):e42-e51
pubmed: 34717820
Front Pharmacol. 2022 Jan 19;12:755600
pubmed: 35126106
J Med Internet Res. 2020 Aug 14;22(8):e20773
pubmed: 32759101
Nat Med. 2013 Jul;19(7):934-8
pubmed: 23770692

Auteurs

Nicolas Hoertel (N)

INSERM U1266, Université Paris Cité, F-75014 Paris, France.
Service de Psychiatrie et Addictologie de l'Adulte et du Sujet Agé, DMU Psychiatrie et Addictologie, Hôpital Corentin-Celton, GHU APHP.Centre, F-92130 Issy-les-Moulineaux, France.

Katayoun Rezaei (K)

Service de Psychiatrie et Addictologie de l'Adulte et du Sujet Agé, DMU Psychiatrie et Addictologie, Hôpital Corentin-Celton, GHU APHP.Centre, F-92130 Issy-les-Moulineaux, France.

Marina Sánchez-Rico (M)

Service de Psychiatrie et Addictologie de l'Adulte et du Sujet Agé, DMU Psychiatrie et Addictologie, Hôpital Corentin-Celton, GHU APHP.Centre, F-92130 Issy-les-Moulineaux, France.
Department of Psychobiology and Behavioural Sciences Methods, Faculty of Psychology, Universidad Complutense de Madrid, 28223 Madrid, Spain.

Alfonso Delgado-Álvarez (A)

Service de Psychiatrie et Addictologie de l'Adulte et du Sujet Agé, DMU Psychiatrie et Addictologie, Hôpital Corentin-Celton, GHU APHP.Centre, F-92130 Issy-les-Moulineaux, France.
Department of Psychobiology and Behavioural Sciences Methods, Faculty of Psychology, Universidad Complutense de Madrid, 28223 Madrid, Spain.
Department of Biological and Health Psychology, Faculty of Psychology, Universidad Autónoma de Madrid, 28049 Madrid, Spain.

Johannes Kornhuber (J)

Department of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander-University of Erlangen-Nuremberg (FAU), 91054 Erlangen, Germany.

Erich Gulbins (E)

Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 47057 Essen, Germany.

Mark Olfson (M)

Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA.

Charles Ouazana-Vedrines (C)

Service de Psychiatrie de l'Adulte, DMU Psychiatrie et Addictologie, Hôpital Hôtel-Dieu, AP-HP, Université Paris Cité, F-75004 Paris, France.

Alexander Carpinteiro (A)

Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 47057 Essen, Germany.
Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University of Duisburg-Essen, 47057 Essen, Germany.

Céline Cougoule (C)

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, 31000 Toulouse, France.

Katrin Anne Becker (KA)

Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 47057 Essen, Germany.

Jesús M Alvarado (JM)

Department of Psychobiology and Behavioural Sciences Methods, Faculty of Psychology, Universidad Complutense de Madrid, 28223 Madrid, Spain.

Frédéric Limosin (F)

INSERM U1266, Université Paris Cité, F-75014 Paris, France.
Service de Psychiatrie et Addictologie de l'Adulte et du Sujet Agé, DMU Psychiatrie et Addictologie, Hôpital Corentin-Celton, GHU APHP.Centre, F-92130 Issy-les-Moulineaux, France.

Classifications MeSH